Booming Gilead blueprints an overhaul of its campus

After more than doubling its work force over the past 6 years, Gilead ($GILD) is investing part of the fortune it has reaped from HIV drugs as well as the hep C therapy Sovaldi in a complete makeover of its big campus in Foster City, CA. The San Francisco Business Times' Ron Leuty reports that Gilead is in the process of tearing down a dozen buildings while erecting 17 new ones on its 73-acre campus. By 2033 the company should have 2.5 million square feet of lab space, office buildings and a new fitness center for staffers to enjoy. Report

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.